Introduction
Temporal lobe epilepsy (TLE) associated with mesial temporal sclerosis (MTS) is one of the most common types of drug-resistant epilepsy referred for surgery 1, 2 . The potential efficacy of resective surgery in patients with drug resistant MTS-TLE is undisputed. However, there are still uncertainties about which patients will benefit most [3] [4] [5] [6] . One of the most consistent risk factors associated with poor outcome after surgery for drug-resistant TLE in the literature is a history of preoperative tonic-clonic seizures [6] [7] [8] [9] . However, no investigators have defined what is meant by the presence of tonic-clonic seizures. It is not clear whether this refers to ongoing recent seizures or more remote seizures, or both. Besides, how the term "remote" should be defined is unknown.
In this study, we evaluated a large surgical cohort, examining seizure outcome during postsurgical follow-up in patients with drug resistant MTS-TLE. The significance of the latency from the last preoperative tonic-clonic seizure to surgery with respect to the outcome after surgery was investigated.
Material and methods
In this retrospective study, all patients with a clinical diagnosis of drug-resistant TLE due to MTS, who underwent epilepsy surgery at the Jefferson Comprehensive Epilepsy Center and had a minimum of one year postoperative follow-up, were assessed. Patients were prospectively registered in a database from 1986 till 2014. Historical data was obtained by board certified neurologists. There was no age limit to enter the study. All patients underwent a comprehensive presurgical evaluation 10 . Magnetic resonance imaging (MRI) studies were analyzed by neuroradiologists, neurologists, and neurosurgeons with expertise in epilepsy. We classified patients as having MTS if they had clear signs of mesial temporal atrophy and/or sclerosis in 4 their brain MRI. Patients with dual pathology and also patients with incomplete data with regard to pre-and postoperative seizure information were excluded. Timing of the last preoperative tonic-clonic seizure was identified. To obtain the most accurate data, we reviewed the medical records of all patients in addition to our database query.
All patients had an anterior temporal lobectomy (ATL) including resection of mesial temporal limbic structures. They were followed for up to five years after surgery. Postsurgical outcome during the follow-up was classified into two groups; with sustained seizure freedom or relapsed (one or more seizures after surgery). Aura was not considered as a relapse; only postoperative tonic-clonic seizures and complex partial seizures were considered as relapse.
Age, gender, epilepsy risk factors (e.g., history of febrile seizures in childhood, family history of epilepsy, etc.), age at seizure onset (i.e., the first afebrile habitual seizure), seizure type(s) and history, date of surgery, date of the first relapse (if any) and date of the last contact with all patients were registered routinely.
Demographic variables and relevant clinical variables were summarized descriptively to characterize the study population. Timing of the last preoperative tonic-clonic seizure was compared between seizure free patients and those who had recurrence. Statistical analyses were performed using Pearson Chi-square, Fisher's exact, Mann-Whitney, and Kolmogorov-Smirnov tests. Time to event analysis was used to produce a Kaplan-Meier estimate of seizure recurrence.
Cox-Mantel test was used to study annual rate of occurrence of first seizure after resective epilepsy surgery. Receiver operating characteristic curve was performed to identify the best cutoff point (maximum sensitivity + specificity) and the discriminatory ability of preoperative tonic-clonic seizures to correctly pick up all patients who had postoperative seizure recurrence. Figure   1 ). The best cutoff point was at 27 months. At this time, the sensitivity was 0.76 and the specificity was 0.60. We then followed up with a Kaplan-Meier curve using the cutoff for preoperative TCS developed from the ROC curve, and confirmed a striking difference in outcomes between recent and distant preoperative TCS. Cox-Mantel analysis confirmed that, the 
Discussion
Tonic-clonic seizures have been observed as a risk factor for seizure recurrence after ATL for drug-resistant MTS-TLE 6 . In one previous study of 116 consecutive patients who had temporal lobe surgery for drug-resistant epilepsy and MTS 9 , the occurrence of generalized tonic-clonic seizures was significantly associated with a poor outcome. In another study of 280 patients who underwent TLE surgery 7 , patients with a history of generalized tonic-clonic seizure(s) were significantly less likely to remain seizure free (odds ratio 0.47, 95% CI 0.25-0.90, p = 0.02).
Another study of 339 patients followed for more than two years found that absence of generalized tonic-clonic seizures and presence of hippocampal atrophy on MRI were significantly associated with remission in patients with medial temporal resection 11 . These findings are consistent, but none clearly defines whether remote tonic-clonic seizures were relevant in the analyses and how they should be considered and defined. The major finding of the current study is that the timing of the last preoperative tonic-clonic seizure correlates with postsurgical seizure outcome, so that for the purpose of determining surgical prognosis, remote tonic-clonic seizures (i.e., seizures more remote than 27 months before surgery) do not count.
Why might this be? Ongoing or recent or more frequent tonic-clonic seizures in a patient with MTS may reflect more widespread epileptogenicity extending beyond the borders of mesial temporal structures. Evidence obtained with fMRI suggests more widespread derangements in brain function and connectivity in TLE patients with tonic-clonic seizures (compared with those without these seizure type) 12 . Lack of tonic-clonic seizure might also indicate a greater preservation or upregulation of inhibitory mechanisms that serve to prevent more extensive spread of ictal discharges to diencephalic and brainstem structures necessary for tonic-clonic seizures 13 . Further investigation of underlying physiology and anatomy is warranted to better define the mechanisms for this process.
Our study has some limitations. Patients in the study had different follow up times after surgery.
Ideally, all patients would have a consistent follow up time, in which case the outcome is simply whether or not a seizure occurred in that interval. Our data does not fit that model. For the purposes of our ROC curve analysis, patients were classified as either having had a postoperative seizure or not, during the available follow up time, which differed between patients. Since most seizures occurred within the first year of follow up (Figure 2) , and the average follow up is over seizure freedom. Therefore, the data in this paper is not completely applicable in those jurisdictions. Finally, many patients (138 patients out of 309 patients; 45%) from our database were excluded from this study due to incomplete seizure data and most importantly, unavailability of the data on the timing of their last preoperative tonic-clonic seizure. This may induce bias.
Conclusions
We evaluated a large surgical cohort, examining seizure outcome during a long-term postsurgical follow-up in patients with MTS-TLE who had undergone epilepsy surgery for drug-resistant seizures. We observed that the timing of the last preoperative tonic-clonic seizure correlates with postsurgical seizure outcome. While a gradual improvement in outcome was noted as tonicclonic seizures became more remote, it appears that one can use a cutoff point of 27 months to predict seizure outcome. Hence, we can refine published observations 6-9 regarding the prognostic significance of preoperative tonic-clonic seizures. The preoperative tonic-clonic seizures do matter, but the more they recede into the distance the less relevant they become. is an editor-in-chief of Epilepsia. 
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